Back
#1
18.6%
Top 2%
8.2%
Top 65%
8.2%
Top 2%
6.7%
Top 40%
6.2%
Top 22%
5.3%
Top 0.5%
4.4%
Top 4%
2.0%
Top 3%
2.0%
Top 3%
2.0%
Top 10%
1.6%
#1
1.6%
Top 1%
1.4%
Top 7%
1.2%
Top 2%
0.8%
Top 13%
0.8%
Top 12%
0.8%
Top 29%
0.8%
Top 14%
0.8%
BCR::ABL1 evaluation in bone marrow is no more predictive of TFR success than from peripheral blood
2025-09-03
hematology
Title + abstract only
View on medRxiv
Show abstract
BackgroundDespite the excellent survival for chronic myeloid leukemia (CML) patients treated with tyrosine kinase inhibitors (TKI), most CML patients report poorer quality of life due to TKI side-effects. In the DESTINY trial (NCT01804985), CML patients halved their TKI dose for 12 months prior to TKI cessation, with 24 months of follow-up off therapy. Enrolled patients (n=174) were in stable deep molecular remission (DMR; BCR::ABL1IS <0.01%) or major molecular response (MMR; BCR::ABL1IS <0.1%),...
Predicted journal destinations
1
Blood Advances
16 training papers
2
eLife
262 training papers
3
PLOS ONE
1737 training papers
4
Frontiers in Immunology
140 training papers
5
Scientific Reports
701 training papers
6
Nature Communications
483 training papers
7
Journal of Clinical Investigation
50 training papers
8
Frontiers in Oncology
34 training papers
9
JCI Insight
63 training papers
10
Clinical Cancer Research
22 training papers
11
Frontiers in Medicine
99 training papers
12
JAMA
17 training papers
13
Science Advances
52 training papers
14
Cancers
57 training papers
15
Cell
28 training papers
16
PLOS Computational Biology
141 training papers
17
iScience
74 training papers
18
JAMA Network Open
125 training papers
19
Vaccines
131 training papers